Details of the Drug

General Information of Drug (ID: DMCHWX1)

Drug Name
Nedosiran
Synonyms DCR-PHXC
Indication
Disease Entry ICD 11 Status REF
Primary hyperoxaluria type 1 5C51.20 Approved [1]
Hyperoxaluria 5C51.2 Phase 2 [2]
Drug Type
Small interfering RNA
Sequence
>Subunit 1
UCAGAUAAAAAGGACAACAUGG
>Subunit 2
AUGUUGUCCUUUUUAUCUGAGCAGCCGAAAGGCUGC
Cross-matching ID
TTD ID
DZ8DF0

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
LDHA messenger RNA (LDHA mRNA) TTW76JE LDHA_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215842
2 ClinicalTrials.gov (NCT04580420) Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD (PHYOX7). U.S. National Institutes of Health.
3 Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098.